Tharimmune, Inc. financial data

Symbol
THAR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1200 Route 22 East, Bridgewater, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Hillstream BioPharma Inc. (to 9/12/2023)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448 % +30.8%
Debt-to-equity 28.8 % -30.4%
Return On Equity -168 % +34%
Return On Assets -130 % +27.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.49M shares -91.5%
Common Stock, Shares, Outstanding 1.28M shares -92.7%
Entity Public Float 3.9M USD -30.4%
Common Stock, Value, Issued 129 USD -92.7%
Weighted Average Number of Shares Outstanding, Basic 1.55M shares +3251%
Weighted Average Number of Shares Outstanding, Diluted 1.55M shares +3251%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.3M USD +63.1%
General and Administrative Expense 5.82M USD +6.94%
Operating Income (Loss) -11.1M USD -27.9%
Nonoperating Income (Expense) 267K USD +179%
Net Income (Loss) Attributable to Parent -10.9M USD -26%
Earnings Per Share, Basic 85.1 USD/shares +93.8%
Earnings Per Share, Diluted 85.1 USD/shares +93.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.77M USD +77.5%
Assets, Current 5.25M USD +65.8%
Assets 5.25M USD +65.8%
Accounts Payable, Current 784K USD -31.2%
Accrued Liabilities, Current 1.37M USD
Liabilities, Current 2.23M USD +58.4%
Liabilities 2.23M USD +58.4%
Retained Earnings (Accumulated Deficit) -33.1M USD -48.8%
Stockholders' Equity Attributable to Parent 3.02M USD +71.8%
Liabilities and Equity 5.25M USD +65.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.83M USD +18.5%
Net Cash Provided by (Used in) Financing Activities 317K USD -39.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.28M shares -92.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.51M USD +14.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.77M USD +77.5%
Deferred Tax Assets, Valuation Allowance 6.68M USD +71.2%
Deferred Tax Assets, Gross 6.68M USD +71.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 36.2M USD +50.4%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 670K USD +21.5%
Interest Expense 15.1K USD -23.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%